Photo of Edward A. Neuwelt, M.D.

Edward A. Neuwelt M.D.

    • Professor of Neurology School of Medicine
    • Neuroscience Graduate Program School of Medicine

After receiving his medical degree from the University of Colorado Medical School, Denver, in 1972, Dr. Neuwelt completed his neurosurgery residency at the University of Texas Southwest Medical School in Dallas. He continued his medical education by completing his neurosurgery fellowship at the Queen Square Hospital in London, England. His special interests include neurooncology and microsurgery. Dr. Neuwelt currently serves as the director of the Blood Brain Barrier Program, and the administrator of the Head and Spinal Cord Injury Prevention Program.

  • Residency:

    • Neurosurgery-University of Texas Southwest Medical School, Dallas
  • Fellowship:

    • Neurosurgery-Queen Square Hospital, London, England

Memberships and associations

  • Neurosurgery, 1980

Publications

  • "The translational significance of the neurovascular unit." Journal of Biological Chemistry In: , Vol. 292, No. 3, 20.01.2017, p. 762-770.
  • "Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431) : a multicentre, randomised, controlled, open-label, phase 3 trial." The Lancet Oncology  In: , Vol. 18, No. 1, 01.01.2017, p. 63-74.
  • "Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab." Fluids and Barriers of the CNS In: , Vol. 13, No. 1, 23, 20.12.2016.
  • "Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific." Nanomedicine: Nanotechnology, Biology, and Medicine In: , Vol. 12, No. 6, 01.08.2016, p. 1535-1542.
  • "Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases : a pilot study with immunohistochemical observations." Journal of Neuro-Oncology In: , 08.07.2016, p. 1-9.
  • "Therapy for secondary CNS involvement inmalignant lymphomas : No standard yet!" Journal of Clinical Oncology  In: , Vol. 34, No. 15, 20.05.2016, p. 1829-1830.
  • "Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity." Journal of Neuro-Oncology In: , Vol. 126, No. 3, 01.02.2016, p. 447-454.
  • "Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults." Investigative Radiology In: , 12.12.2015.
  • "Dose-dependent neurotoxicity (seizures) due to deposition of gadolinium-based contrast agents in the central nervous system." Radiology In: , Vol. 277, No. 3, 01.12.2015, p. 925-926.
  • "Interactions between αv-Integrin and HER2 and their role in the invasive phenotype of breast cancer cells in vitro and in rat brain." PLoS One In: , Vol. 10, No. 7, e0131842, 29.07.2015.
  • "Mapping human brain capillary water lifetime : High-resolution metabolic neuroimaging." NMR in Biomedicine In: , Vol. 28, No. 6, 01.06.2015, p. 607-623.
  • "Unsanctifying the sanctuary : Challenges and opportunities with brain metastases." Neuro-Oncology  In: , Vol. 17, No. 5, 01.05.2015, p. 639-651.
  • "Primary CNS lymphoma." Neurology  In: , Vol. 84, No. 12, 24.03.2015, p. 1194-1195.
  • "Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis." Fluids and Barriers of the CNS In: , Vol. 12, No. 1, 5, 17.02.2015.
  • "N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models." Journal of Neuro-Oncology In: , Vol. 121, No. 3, 2015, p. 433-440.
  • "Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival." CNS oncology In: , Vol. 3, No. 6, 01.11.2014, p. 389-400.
  • "Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis." CNS oncology In: , Vol. 3, No. 4, 01.07.2014, p. 267-273.
  • "Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question." Neuro-Oncology In: , Vol. 16, No. 8, 2014, p. 1146-1154.
  • "Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors." Pediatric Blood and Cancer In: , Vol. 61, No. 1, 2014, p. 120-127.
  • "Delivery of chemotherapeutics across the blood-brain barrier : Challenges and advances." Advances in Pharmacology In: , Vol. 71, 2014, p. 203-243.
  • "Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder." Journal of NeuroVirology In: , Vol. 19, No. 6, 12.2013, p. 601-605.
  • "Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery." Journal of Clinical Oncology In: , Vol. 31, No. 31, 01.11.2013, p. 4026-4027.
  • "Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL." Neurology In: , Vol. 81, No. 3, 16.07.2013, p. 256-263.
  • "Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma." Neurology In: , Vol. 81, No. 1, 02.07.2013, p. 84-92.
  • "Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma." Anticancer Research In: , Vol. 33, No. 6, 06.2013, p. 2391-2400.
  • "High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle." Journal of Cerebral Blood Flow and Metabolism In: , Vol. 33, No. 5, 05.2013, p. 780-786.
  • "A 67-year-old woman receiving tumor necrosis factor α inhibitor therapy presenting with neurologic dysfunction." Arthritis Care and Research In: , Vol. 65, No. 4, 04.2013, p. 658-665.
  • "Pseudoprogression of glioblastoma after chemo- and radiation therapy : Diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival." Radiology In: , Vol. 266, No. 3, 03.2013, p. 842-852.
  • "Immunologic privilege in the central nervous system and the blood-brain barrier." Journal of Cerebral Blood Flow and Metabolism In: , Vol. 33, No. 1, 01.2013, p. 13-21.
  • "The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma : Laboratory investigation." Journal of Neurosurgery: Pediatrics In: , Vol. 11, No. 1, 01.2013, p. 60-67.

Additional information

Edit profile